- Home
- BOLD vs TLPH Comparison
BOLD vs TLPH Comparison
Compare BOLD & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BOLD | TLPH |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.5M | 54.5M |
| IPO Year | 2024 | 2010 |
Fundamental Metrics
Financial Performance| Metric | BOLD | TLPH |
|---|---|---|
| Price | $2.45 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.13 |
| AVG Volume (30 Days) | ★ 120.3K | 76.2K |
| Earning Date | 11-24-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,151,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.96 | $0.69 |
| 52 Week High | $3.16 | $1.57 |
Technical Indicators
Market Signals| Indicator | BOLD | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 47.13 | 51.64 |
| Support Level | $2.43 | $1.03 |
| Resistance Level | $2.65 | $1.14 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 37.50 | 50.71 |
Price Performance
Historical ComparisonAbout BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.